KOBV Portal

Hits per page

hits 1 - 10 | 834 hits

Sorting

Online Resource

miRTarBase 2020: updates to the experimentally validated microRNA–target interaction database

Huang, Hsi-Yuan ; Lin, Yang-Chi-Dung ; Li, Jing ; [et al.]

Oxford University Press (OUP) ; 2019

In: Nucleic Acids Research ( 2019-10-24)

add to watchlist on the watchlist

Details

In: Nucleic Acids Research, Oxford University Press (OUP), ( 2019-10-24)

Abstract: MicroRNAs (miRNAs) are small non-coding RNAs (typically consisting of 18–25 nucleotides) that negatively control expression of target genes at the post-transcriptional level. Owing to the biological significance of miRNAs, miRTarBase was developed to provide comprehensive information on experimentally validated miRNA–target interactions (MTIs). To date, the database has accumulated 〉 13,404 validated MTIs from 11,021 articles from manual curations. In this update, a text-mining system was incorporated to enhance the recognition of MTI-related articles by adopting a scoring system. In addition, a variety of biological databases were integrated to provide information on the regulatory network of miRNAs and its expression in blood. Not only targets of miRNAs but also regulators of miRNAs are provided to users for investigating the up- and downstream regulations of miRNAs. Moreover, the number of MTIs with high-throughput experimental evidence increased remarkably (validated by CLIP-seq technology). In conclusion, these improvements promote the miRTarBase as one of the most comprehensively annotated and experimentally validated miRNA–target interaction databases. The updated version of miRTarBase is now available at http://miRTarBase.cuhk.edu.cn/.

Type of Medium: Online Resource

ISSN: 0305-1048 , 1362-4962

URL: Article

DOI: 10.1093/nar/gkz896

RVK:

WA 15000

Language: English

Publisher: Oxford University Press (OUP)

Publication Date: 2019

detail.hit.zdb_id: 1472175-2

SSG: 12

Bookmarklink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Online Resource

Open Access Request

Availability (electronic / print)

Link to publisher

Online Resource

Two new C-glycosylflavones from Boea hygrometrica

Feng, Wei-Sheng ; Li, Yuan-Jing ; Zheng, Xiao-Ke ; [et al.]

Informa UK Limited ; 2011

In: Journal of Asian Natural Products Research Vol. 13, No. 7 ( 2011-07), p. 618-623

add to watchlist on the watchlist

Details

In: Journal of Asian Natural Products Research, Informa UK Limited, Vol. 13, No. 7 ( 2011-07), p. 618-623

Type of Medium: Online Resource

ISSN: 1028-6020 , 1477-2213

URL: Article

DOI: 10.1080/10286020.2011.579903

Language: English

Publisher: Informa UK Limited

Publication Date: 2011

detail.hit.zdb_id: 2077926-4

Bookmarklink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Online Resource

Open Access Request

Availability (electronic / print)

Link to publisher

Online Resource

Epidemiology of the first 100 cases of COVID-19 in Taiwan and its implications on outbreak control

Tsou, Tsung-Pei ; Chen, Wan-Chin ; Huang, Angela Song-En ; [et al.]

Elsevier BV ; 2020

In: Journal of the Formosan Medical Association Vol. 119, No. 11 ( 2020-11), p. 1601-1607

add to watchlist on the watchlist

Details

In: Journal of the Formosan Medical Association, Elsevier BV, Vol. 119, No. 11 ( 2020-11), p. 1601-1607

Type of Medium: Online Resource

ISSN: 0929-6646

URL: Article

DOI: 10.1016/j.jfma.2020.07.015

Language: English

Publisher: Elsevier BV

Publication Date: 2020

detail.hit.zdb_id: 2250901-X

Bookmarklink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Online Resource

Open Access Request

Availability (electronic / print)

Link to publisher

Online Resource

Sofosbuvir/velpatasvir/voxilaprevir for patients with chronic hepatitis C virus infection previously treated with NS5A direct-acting antivirals: a real-world multicenter cohort in Taiwan

Liu, Chen-Hua ; Peng, Cheng-Yuan ; Liu, Chun-Jen ; [et al.]

Springer Science and Business Media LLC ; 2023

In: Hepatology International Vol. 17, No. 2 ( 2023-04), p. 291-302

add to watchlist on the watchlist

Details

In: Hepatology International, Springer Science and Business Media LLC, Vol. 17, No. 2 ( 2023-04), p. 291-302

Type of Medium: Online Resource

ISSN: 1936-0533 , 1936-0541

URL: Article

DOI: 10.1007/s12072-022-10475-9

Language: English

Publisher: Springer Science and Business Media LLC

Publication Date: 2023

detail.hit.zdb_id: 2270316-0

Bookmarklink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Online Resource

Open Access Request

Availability (electronic / print)

Link to publisher

Online Resource

Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis

Liu, Chen-Hua ; Chen, Chi-Yi ; Su, Wei-Wen ; [et al.]

The Korean Association for the Study of the Liver ; 2021

In: Clinical and Molecular Hepatology Vol. 27, No. 4 ( 2021-10-01), p. 575-588

add to watchlist on the watchlist

Details

In: Clinical and Molecular Hepatology, The Korean Association for the Study of the Liver, Vol. 27, No. 4 ( 2021-10-01), p. 575-588

Abstract: Background/Aims: Real-world studies assessing the effectiveness and safety of sofosbuvir/velpatasvir (SOF/VEL) plus ribavirin (RBV) for Child-Pugh B/C hepatitis C virus (HCV)-related cirrhosis are limited.Methods: We included 107 patients with Child-Pugh B/C HCV-related cirrhosis receiving SOF/VEL plus RBV for 12 weeks in Taiwan. The sustained virologic response rates at off-treatment week 12 (SVR12) for the evaluable population (EP), modified EP, and per-protocol population (PP) were assessed. Thesafety profiles were reported.Results: The SVR12 rates in the EP, modified EP and PP were 89.7% (95% confidence interval [CI] , 82.5–94.2%), 94.1% (95% CI, 87.8–97.3%), and 100% (95% CI, 96.2–100%). Number of patients who failed to achieve SVR12 were attributed to virologic failures. The SVR12 rates were comparable regardless of patient characteristics. One patient discontinued treatment because of adverse events (AEs). Twenty-four patients had serious AEs and six died, but none were related to SOF/VEL or RBV. Among the 96 patients achieving SVR12, 84.4% and 64.6% had improved Child-Pugh and model for endstage liver disease (MELD) scores. Multivariate analysis revealed that a baseline MELD score ≥15 was associated with an improved MELD score of ≥3 (odds ratio, 4.13; 95% CI, 1.16–14.71; P=0.02). Patients with chronic kidney disease (CKD) stage 1 had more significant estimated glomerular filtration rate declines than patients with CKD stage 2 (-0.42 mL/min/1.73 m2/month; P=0.01) or stage 3 (-0.56 mL/min/1.73 m2/month; P 〈 0.001).Conclusions: SOF/VEL plus RBV for 12 weeks is efficacious and well-tolerated for Child-Pugh B/C HCV-related cirrhosis.

Type of Medium: Online Resource

ISSN: 2287-2728 , 2287-285X

URL: Article

DOI: 10.3350/cmh.2021.0155

Language: English

Publisher: The Korean Association for the Study of the Liver

Publication Date: 2021

detail.hit.zdb_id: 2672531-9

Bookmarklink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Online Resource

Open Access Request

Availability (electronic / print)

Link to publisher

Online Resource

Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan

Liu, Chen-Hua ; Chen, Po-Yueh ; Chen, Jyh-Jou ; [et al.]

Springer Science and Business Media LLC ; 2021

In: Hepatology International Vol. 15, No. 2 ( 2021-04), p. 338-349

add to watchlist on the watchlist

Details

In: Hepatology International, Springer Science and Business Media LLC, Vol. 15, No. 2 ( 2021-04), p. 338-349

Type of Medium: Online Resource

ISSN: 1936-0533 , 1936-0541

URL: Article

DOI: 10.1007/s12072-021-10158-x

Language: English

Publisher: Springer Science and Business Media LLC

Publication Date: 2021

detail.hit.zdb_id: 2270316-0

Bookmarklink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Online Resource

Open Access Request

Availability (electronic / print)

Link to publisher

Online Resource

Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment

Liu, Chen-Hua ; Chen, Chi-Yi ; Su, Wei-Wen ; [et al.]

BMJ ; 2022

In: Gut Vol. 71, No. 1 ( 2022-01), p. 176-184

add to watchlist on the watchlist

Details

In: Gut, BMJ, Vol. 71, No. 1 ( 2022-01), p. 176-184

Abstract: Data regarding the real-world effectiveness and safety of sofosbuvir/velpatasvir (SOF/VEL) with or without low-dose ribavirin (RBV) in patients with chronic hepatitis C virus (HCV) infection and severe renal impairment (RI) are limited. We evaluated the performance of SOF/VEL with or without low-dose RBV in HCV-infected patients with chronic kidney disease stage 4 or 5. Design 191 patients with compensated (n=181) and decompensated (n=10) liver diseases receiving SOF/VEL (400/100 mg/day) alone and SOF/VEL with low-dose RBV (200 mg/day) for 12 weeks were retrospectively recruited at 15 academic centres in Taiwan. The effectiveness was determined by sustained virological response at off-treatment week 12 (SVR 12 ) in evaluable (EP) and per-protocol populations (PP). The safety profiles were assessed. Results The SVR 12 rates by EP and PP analyses were 94.8% (95% CI 90.6% to 97.1%) and 100% (95% CI 97.9% to 100%). In patients with compensated liver disease, the SVR 12 rates were 95.0% and 100% by EP and PP analyses. In patients with decompensated liver disease, the SVR 12 rates were 90.0% and 100% by EP and PP analyses. Ten patients who failed to achieve SVR 12 were attributed to non-virological failures. Among the 20 serious adverse events (AEs), none were judged related to SOF/VEL or RBV. The AEs occurring in ≥10% included fatigue (14.7%), headache (14.1%), nausea (12.6%), insomnia (12.0%) and pruritus (10.5%). None had ≥grade 3 total bilirubin or alanine aminotransferase elevations. Conclusion SOF/VEL with or without low-dose RBV is effective and well-tolerated in HCV-infected patients with severe RI.

Type of Medium: Online Resource

ISSN: 0017-5749 , 1468-3288

URL: Article

DOI: 10.1136/gutjnl-2020-323569

RVK:

XA 10000

Language: English

Publisher: BMJ

Publication Date: 2022

detail.hit.zdb_id: 1492637-4

Bookmarklink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Online Resource

Open Access Request

Availability (electronic / print)

Link to publisher

Online Resource

Comparing the controlled attenuation parameter using FibroScan and attenuation imaging with ultrasound as a novel measurement for liver steatosis

Hsu, Po-Ke ; Wu, Li-Sha ; Su, Wei-Wen ; [et al.]

Public Library of Science (PLoS) ; 2021

In: PLOS ONE Vol. 16, No. 10 ( 2021-10-15), p. e0254892-

add to watchlist on the watchlist

Details

In: PLOS ONE, Public Library of Science (PLoS), Vol. 16, No. 10 ( 2021-10-15), p. e0254892-

Abstract: In a recent study, attenuation imaging (ATI) with ultrasound was used as a new approach for detecting liver steatosis. However, although there are many studies on ATI and controlled attenuation parameter (CAP) that prove their practicability, there are few studies comparing these two methods. As such, this study compared CAP and ATI for the detection and evaluation of liver steatosis. Methods A prospective analysis of 28 chronic liver disease patients who underwent liver biopsy, FibroScan® imaging, and ATI with ultrasound was conducted. The presence and degree of steatosis, as measured with the FibroScan® device and ATI, were compared with the pathological results obtained using liver biopsy. Results The areas under the receiver operating characteristic curve (AUROC) of ATI and CAP for differentiating between normal and hepatic steatosis were 0.97 (95% confidence interval [CI] 0.83–1.00) and 0.96 (95% CI 0.81–0.99), respectively. ATI has a higher AUROC than CAP does in liver steatosis, at 0.99 (95% CI, 0.86–1.00) versus 0.91 (95% CI, 0.74–0.98) in grade ≥ 2 and 0.97 (95% CI, 0.82–1.00) versus 0.88 (95% CI, 0.70–0.97) in grade = 3, respectively. Conclusion The ATI and CAP results showed good consistency and accuracy for the steatosis grading when compared with the liver biopsy results. Moreover, ATI is even better than CAP in patients with moderate or severe steatosis. Therefore, ATI represents a non-invasive and novel diagnostic tool with which to support the diagnosis of liver steatosis in clinical practice.

Type of Medium: Online Resource

ISSN: 1932-6203

URL: Article

DOI: 10.1371/journal.pone.0254892

DOI: 10.1371/journal.pone.0254892.g001

DOI: 10.1371/journal.pone.0254892.g002

DOI: 10.1371/journal.pone.0254892.g003

DOI: 10.1371/journal.pone.0254892.g004

DOI: 10.1371/journal.pone.0254892.g005

DOI: 10.1371/journal.pone.0254892.t001

DOI: 10.1371/journal.pone.0254892.t002

DOI: 10.1371/journal.pone.0254892.s001

DOI: 10.1371/journal.pone.0254892.s002

DOI: 10.1371/journal.pone.0254892.s003

DOI: 10.1371/journal.pone.0254892.r001

DOI: 10.1371/journal.pone.0254892.r002

DOI: 10.1371/journal.pone.0254892.r003

DOI: 10.1371/journal.pone.0254892.r004

DOI: 10.1371/journal.pone.0254892.r005

DOI: 10.1371/journal.pone.0254892.r006

Language: English

Publisher: Public Library of Science (PLoS)

Publication Date: 2021

detail.hit.zdb_id: 2267670-3

Bookmarklink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Online Resource

Open Access Request

Availability (electronic / print)

Link to publisher

Online Resource

E管系統提升B、C肝病人追蹤照護品質

劉怡伶, 劉怡伶 ; Yi-Lin Liou, 楊媛淇 ; Yuan-Chi Yang, 曾雅慧 ; [et al.]

Angle Publishing Co., Ltd. ; 2022

In: 醫療品質雜誌 Vol. 16, No. 2 ( 2022-03), p. 032-037

add to watchlist on the watchlist

Details

In: 醫療品質雜誌, Angle Publishing Co., Ltd., Vol. 16, No. 2 ( 2022-03), p. 032-037

Abstract: 〈p〉B、C型肝炎病人需要定期追蹤及檢驗疾病發展狀況，以及早發現肝癌。彰化基督教醫院胃腸肝膽科於2010年開始實行衛生福利部中央健康保險署（下稱健保署）追蹤照護計畫，過程中因病人病識感低，以及門診收案及追蹤流程複雜，截至2016年收案率14.6%、年度完整追蹤率28.8%，皆未達健保署設定的3項品質獎勵監測指標。透過E化之B、C肝照護管理系統，改善並簡化門診收案流程，提升個案管理師收案追蹤效率及提高病人遵從醫囑率，大幅提升了B、C肝病人照護品質。於2017年開始執行E化追蹤管理，2019年收案率提升至58.91%(4542/7710)，年度完整追蹤率達74.45%(3107/4173)。健保署評比2018年度品質獎勵榮獲中區第一名，本院是中區唯一獲得品質獎勵之醫學中心。〈/p〉 〈p〉 〈/p〉〈p〉Patients with hepatitis B and C require regular follow-up to monitor disease activity and screen for the presence of hepatocellular carcinoma. Since 2010, Changhua Christian Hospital has implemented a hepatitis B and C care plan guided by the National Health Insurance Administration (NHIA), Ministry of Health and Welfare (MOHW). The rates of patient enrollment and follow-up between 2010 and 2016 were unsatisfactory. The annual enrollment and follow-up rates were only 14.6% and 28.8%, respectively, in 2016, falling below the three quality indicator standards established by the NHIA. The absence of insight into patient disease and the complexity of patient enrollment and follow-up procedures were identified as the main problems. Therefore, in 2017, we developed a strategy for improving and simplifying the patient enrollment process, enhancing the efficiency of the case managers involved in patient enrollment and follow-up, and increasing the rate of medical compliance. An electronic follow-up reminder system was implemented to enhance our quality of care among patients with hepatitis B and C. Thus, in 2019, the annual enrollment and follow-up rates had dramatically increased to 58.91% (4542/7710) and 74.45% (3107/4173), respectively. Because of the improved care management system, our hospital was the only medical center in central Taiwan that won an NHI Quality Award in 2018.〈/p〉 〈p〉 〈/p〉

Type of Medium: Online Resource

ISSN: 1994-5795 , 1994-5795

Uniform Title: Enhancing the Quality of Follow-Up Care for Patients With Hepatitis B and C Using an Electronic Reminder System: A 2016-2019 Hospital-Based Study

URL: Article

DOI: 10.53106/199457952022031602005

Language: Unknown

Publisher: Angle Publishing Co., Ltd.

Publication Date: 2022

Bookmarklink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Online Resource

Open Access Request

Availability (electronic / print)

Link to publisher

Online Resource

Comparison of Machine Learning Models and the Fatty Liver Index in Predicting Lean Fatty Liver

Su, Pei-Yuan ; Chen, Yang-Yuan ; Lin, Chun-Yu ; [et al.]

MDPI AG ; 2023

In: Diagnostics Vol. 13, No. 8 ( 2023-04-13), p. 1407-

add to watchlist on the watchlist

Details

In: Diagnostics, MDPI AG, Vol. 13, No. 8 ( 2023-04-13), p. 1407-

Abstract: The reported prevalence of non-alcoholic fatty liver disease in studies of lean individuals ranges from 7.6% to 19.3%. The aim of the study was to develop machine-learning models for the prediction of fatty liver disease in lean individuals. The present retrospective study included 12,191 lean subjects with a body mass index 〈 23 kg/m2 who had undergone a health checkup from January 2009 to January 2019. Participants were divided into a training (70%, 8533 subjects) and a testing group (30%, 3568 subjects). A total of 27 clinical features were analyzed, except for medical history and history of alcohol or tobacco consumption. Among the 12,191 lean individuals included in the present study, 741 (6.1%) had fatty liver. The machine learning model comprising a two-class neural network using 10 features had the highest area under the receiver operating characteristic curve (AUROC) value (0.885) among all other algorithms. When applied to the testing group, we found the two-class neural network exhibited a slightly higher AUROC value for predicting fatty liver (0.868, 0.841–0.894) compared to the fatty liver index (FLI; 0.852, 0.824–0.81). In conclusion, the two-class neural network had greater predictive value for fatty liver than the FLI in lean individuals.

Type of Medium: Online Resource

ISSN: 2075-4418

URL: Article

DOI: 10.3390/diagnostics13081407

Language: English

Publisher: MDPI AG

Publication Date: 2023

detail.hit.zdb_id: 2662336-5

Bookmarklink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Online Resource

Open Access Request

Availability (electronic / print)

Link to publisher

hits 1 - 10 | 834 hits

Nothing or not found what you are looking for? Please check your search query or use the Interlibrary Loan Search.

Kooperativer Bibliotheksverbund

Berlin Brandenburg